These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18429700)

  • 1. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice.
    Shulman LP; Portman DJ; Lee WC; Balu S; Joshi AV; Cobden D; Wang Q; Pashos CL
    J Womens Health (Larchmt); 2008 May; 17(4):569-78. PubMed ID: 18429700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance to vaginal treatment-tablets versus cream: a retrospective 9 years study.
    Weissmann-Brenner A; Bayevsky T; Yoles I
    Menopause; 2017 Jan; 24(1):73-76. PubMed ID: 27648663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.
    Portman D; Shulman L; Yeaw J; Zeng S; Uzoigwe C; Maamari R; Iyer NN
    Menopause; 2015 Nov; 22(11):1197-203. PubMed ID: 25944522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal estrogen therapy for the treatment of atrophic vaginitis.
    Lynch C
    J Womens Health (Larchmt); 2009 Oct; 18(10):1595-606. PubMed ID: 19788364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

  • 6. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
    Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
    Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.
    Nappi RE; Kokot-Kierepa M
    Climacteric; 2012 Feb; 15(1):36-44. PubMed ID: 22168244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors related to antipsychotic oversupply among Central Texas Veterans.
    Yang M; Barner JC; Worchel J
    Clin Ther; 2007 Jun; 29(6):1214-25. PubMed ID: 17692735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting estrogen through the skin.
    Harv Womens Health Watch; 1998 Dec; 6(4):2-3. PubMed ID: 9846142
    [No Abstract]   [Full Text] [Related]  

  • 12. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream.
    Bhamra RK; Margolis MB; Liu JH; Hendy CH; Jenkins RG; DiLiberti CE
    Menopause; 2011 Apr; 18(4):393-9. PubMed ID: 21107298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
    Hertz RP; Unger AN; Lustik MB
    Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
    Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
    Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
    Crandall C
    J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA; Victor Spain C; Alexander CM; Simmons J
    Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications.
    Al-Zakwani IS; Barron JJ; Bullano MF; Arcona S; Drury CJ; Cockerham TR
    Curr Med Res Opin; 2003; 19(7):619-26. PubMed ID: 14606985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
    Simon JA; Maamari RV
    Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.